Advertisement
Advertisement
Money /

Markets & Investing

Healthcare led liquidity growth on the Hong Kong stock market over the past decade, with trading turnover for the sector surging more than 11-fold between 2015 and 2025. Photo: Shutterstock
Banking & finance

Biotech-led boom as 8 China firms flock to Hong Kong’s thriving stock market

AI-powered drug developer Metis TechBio leads group that includes developers of autonomous driving technology and industrial robots.

Banking & finance

Liquid courage: Hong Kong fund pitches whisky as alternative investment

Banking & finance

Global funds fuel Hong Kong IPO rebound as investors rebalance China portfolios

Banking & finance

China healthcare stocks shine in Hong Kong amid Middle East turmoil

Hang Seng Healthcare Index outpaces broader market as Akeso, Innovent, Hansoh provide refuge for global investors.

A number of Chinese biopharmaceutical and biotech companies posted their first-ever annual profits in 2025. Photo: Shutterstock
A number of Chinese biopharmaceutical and biotech companies posted their first-ever annual profits in 2025. Photo: Shutterstock
Banking & finance

OKX Ventures, HashKey Capital back Vietnam crypto platform’s pilot scheme bid

Under pilot rules, at least 65 per cent of capital must come from institutional investors and foreign ownership is capped at 49 per cent.

Banking & finance

Mainland China and Hong Kong IPOs drive Citic to the top of banking fee rankings

Citic leads Asia-Pacific in fees in the first quarter as IPOs in Hong Kong and mainland China offset weaker debt and M&A activity.

Advertisement
Advertisement
Advertisement
Banking & finance

Everest’s US$250 million buy signals rising global appetite for China biotech

Sovereign wealth funds from Singapore and Abu Dhabi join Chinese state capital as cross-border biotech licensing reaches record highs.

Cross-border out-licensing by Chinese drugmakers has reached a record US$60 billion in the first three months of the year. Photo: Shutterstock
Cross-border out-licensing by Chinese drugmakers has reached a record US$60 billion in the first three months of the year. Photo: Shutterstock
Banking & finance

Stricter Chinese scrutiny of offshore vehicles a blow for tech IPO candidates

Mainland’s stock market watchdog is discouraging establishment of ‘red-chip-structured’ companies in sensitive industries.

Banking & finance

Hong Kong’s anticipated stablecoin licence by end-March does not materialise

Analysts say the delay is most likely administrative and that the overall plan is still on track.

videocam
IPO

Hong Kong retains IPO crown but may lose to US mega listings over full year

Second place for IPO funds raised is Nasdaq, with US$5.65 billion from 18 listings, while the New York Stock Exchange ranks third.

An exterior view of the Hong Kong stock exchange in Central, February 6, 2026. Photo: Jonathan Wong
Mainland China

Sketching a recovery: China puts next-gen art buyers in the frame amid slowdown

A US$83 trillion global wealth transfer in next two to three decades is beginning to reshape China’s art market: UBS.

Tracey Emin’s “Take me to Heaven” on display at Art Basel in Hong Kong. Wealth managers are increasingly targeting a younger cohort when it comes to art investment. Photo: Enid Tsui
Tracey Emin’s “Take me to Heaven” on display at Art Basel in Hong Kong. Wealth managers are increasingly targeting a younger cohort when it comes to art investment. Photo: Enid Tsui
Turkey

As tensions rise, Middle Eastern money and travellers pivot to Hong Kong

Wealthy Gulf visitors are extending their stays in Hong Kong as investors from the region look to hedge risk and tap Asian markets.

Banking & finance

Tong Ren Tang unit pulls Hong Kong IPO in first postponement this year

Hospital-network operator delays plan to raise up to US$115 million amid tepid demand.

videocam
China’s private sector

China’s obesity drug makers take on global giants as Novo Nordisk patent expires

Patent expiry of blockbuster drug opens door for Chinese drug makers to challenge multinationals in booming weight-loss market.

Semaglutide generated about US$35 billion in global revenue last year. Photo: AFP
China’s private sector

Rights to antibody drug from China’s Keymed change hands in US acquisition

Sichuan-based Keymed expects to receive up to US$320 million as a result of deal involving its autoimmune disease treatment licensed in 2024.

Gilead Sciences is one of many drug firms facing a revenue gap owing to expiring patents. Photo: Reuters
Gilead Sciences is one of many drug firms facing a revenue gap owing to expiring patents. Photo: Reuters
Banking & finance

Asian private equity values cash flow as fundraising falls to 12-year low

Advanced manufacturing and healthcare attract more attention at the expense of technology, media and telecommunications, Bain & Co says.

Made in China 2025

Global drug giants double down on China amid push for self-reliant supply chains

Multinationals are building self-reliant supply chains in China to insulate local markets from potential trade disruptions, say analysts.

Advertisement
Advertisement
Advertisement
Banking & finance

Iran conflict drives fund managers to slash risk and hoard cash: BofA survey

Fund managers pile into cash at fastest pace since Covid-19 as geopolitical tensions, inflation replace AI as top concerns, bank finds.

Investor sentiment fell to a six-month low in March, according to a BofA report. Photo: AFP
Investor sentiment fell to a six-month low in March, according to a BofA report. Photo: AFP
Banking & finance

Chinese banks outpace rivals in Hong Kong wealth growth, Huatai HK CEO says

Booming listings and rising outbound investment demand are accelerating growth for Chinese players, SFC data shows.

China’s private sector

US reshoring drive casts shadow over China’s contract drug makers, analyst says

Strong order backlogs underpin earnings through 2027, but analysts warn longer-term demand is less certain as US firms reshore production.

Hong Kong stock market

Hong Kong stocks edge higher as oil steadies, tracking Wall Street gains

Hang Seng Index advances for a second day amid easing concerns over inflation and geopolitical risks.

A motorist holds a fuel pump nozzle to fill up his car. Photo: AFP
Banking & finance

Hong Kong attracts wave of biotech IPO filings amid AI drug research boom

More than 10 pre-profit drug developers are seeking Hong Kong listings as AI-powered biotech platforms draw growing investor interest.

The latest applications come as healthcare and biotechnology equity capital market activity in Hong Kong reached US$15.6 billion last year. Illustration: Shutterstock
The latest applications come as healthcare and biotechnology equity capital market activity in Hong Kong reached US$15.6 billion last year. Illustration: Shutterstock
China stock market

Hopes of AI monetisation to boost China tech stocks amid war, market scares

Chinese tech stocks prove steadier than regional and US peers, as frenzy over OpenClaw shows a possible way forward, analysts say.

Biomedicine: Companies

In a first for China, Neuracle’s brain-computer interface wins approval

China’s BCI start-ups, seen as potential rivals to Elon Musk’s Neuralink, gain momentum as regulatory support and new capital fuel growth.

Banking & finance

China investors energise Hong Kong biotech stocks. Is foreign money missing out?

Stock Connect reshuffle reflects biotech sector’s growing role on international stage, though overseas funds remain cautious.

Overseas capital tends to cherry-pick a few big-cap pharmaceutical companies rather than buy the biotech sector broadly, according to an analyst. Photo: Handout
Help preserve 120 years of quality journalism.
SUPPORT NOW